NASDAQ:HURA
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$27.7M, and the diluted share count rose 156.8%.Summary generated from TuHURA Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−169.2%
Debt / equityn/a
Free cash flow−$27.7M
FCF marginn/a
Share count change+156.8%
Financials
| Item | 2012 | 2013 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 0 | 0 |
| Operating income | n/a | n/a | n/a | n/a | n/a |
| Net income | −2 | −8 | −29 | −22 | −30 |
| Free cash flow | n/a | n/a | −12 | −15 | −28 |
Recent filings
- 8-KNew financial obligation
Sep 24, 2026 - 8-KNew financial obligation
Sep 17, 2026 - 8-K/AAmended director or officer change
Sep 17, 2026 - 8-KDirector or officer change
Sep 16, 2026 - 8-KNew financial obligation
Sep 4, 2026 - 8-KNew financial obligation
Aug 21, 2026 - 8-KResults of a shareholder vote
Aug 19, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026